Elgan Pharma Ltd.
Clinical trials sponsored by Elgan Pharma Ltd., explained in plain language.
-
New drug aims to help tiniest babies absorb nutrients safely
Disease control Recruiting nowThis study tests whether a new medicine called ELGN-2112 is safe for very premature babies (born before 26 weeks) and for growth-restricted babies born between 26 and 32 weeks. About 60 infants will receive either the medicine or a placebo. The goal is to see if the drug can help…
Phase: PHASE2 • Sponsor: Elgan Pharma Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New treatment aims to help premature babies absorb food better
Disease control Recruiting nowThis study is testing whether a drug called ELGN-2112 can help premature babies with intestinal malabsorption, a condition where their gut struggles to absorb nutrients. It will involve 360 infants born between 26 and 32 weeks of pregnancy. The main goal is to see if the treatmen…
Phase: PHASE3 • Sponsor: Elgan Pharma Ltd. • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC